25 Safety Pharmacology CROs

What is safety pharmacology and when do you need it?

Safety pharmacology is the set of studies that asks a narrow but unforgiving question: at the doses you plan to give, does your drug interfere with the vital functions a body cannot do without. That is mainly the cardiovascular system, the central nervous system, and the respiratory system, the so-called core battery defined in ICH S7A. These are not the same as your general toxicology studies. Toxicology looks for tissue damage over days and weeks of repeat dosing; safety pharmacology looks for acute functional effects, usually after a single dose, on systems where a sudden change can be fatal before any tissue ever shows a lesion.

You need this work in the run-up to your IND, as part of the IND-enabling package, before the first human is dosed. The timing is deliberate. A regulator reading your IND wants to know not only what organ might eventually be harmed, but whether dosing a healthy Phase 1 volunteer could trigger an arrhythmia, a seizure, or respiratory depression within hours. Cardiac liability gets special attention because of the long history of drugs that prolonged the QT interval and caused torsade de pointes, which is why ICH S7B and the in vitro hERG assay sit at the center of most programs.

In practice, safety pharmacology runs in parallel with your pivotal GLP toxicology, not after it, and often shares the same animals and bioanalytical methods. The pivotal core-battery studies are GLP. Earlier de-risking work, an early non-GLP hERG screen or a functional observational read during dose-range finding, can run non-GLP so you catch a fatal flaw cheaply before committing to the expensive pivotal studies.

What does a safety pharmacology CRO actually do?

A safety pharmacology CRO runs the functional studies that make up the core battery, plus the cardiac work that regulators scrutinize hardest. The cardiovascular study is usually done in a conscious, telemetered large animal (dog or non-human primate), measuring blood pressure, heart rate, and the ECG, with the QT interval corrected for heart rate as the headline endpoint. The CNS study is typically a functional observational battery or an Irwin screen in rodents, scoring behavior, reflexes, body temperature, and signs of stimulation or sedation. The respiratory study uses whole-body plethysmography in conscious rodents to capture respiratory rate, tidal volume, and minute volume.

On the cardiac side, the in vitro hERG assay (a patch-clamp measurement of the potassium channel that governs cardiac repolarization) is the standard ICH S7B screen for QT-prolongation risk. Many programs now also run the newer in vitro approaches, including multi-ion-channel panels and human stem-cell-derived cardiomyocyte assays under the CiPA framework, which some sponsors use to build a stronger mechanistic story around an ambiguous hERG signal.

A capable CRO does more than generate traces. It designs the study to support the doses and exposures in your planned first-in-human trial, runs the bioanalytical and toxicokinetic sampling that ties effects to plasma concentration, and writes a GLP report a reviewer can read without follow-up questions. Some sponsors also integrate ECG and functional observations into the repeat-dose toxicology studies under ICH S7A to save animals and time, though a dedicated telemetry study usually gives a cleaner QT read. Supplemental studies (renal, gastrointestinal, autonomic) get added only when the core battery, the pharmacology, or the chemical class flags a specific concern.

How do you choose a safety pharmacology CRO?

The cheapest quote almost never wins here. A core-battery study that has to be repeated, or worse, a QT signal a reviewer does not trust, costs far more in delay than any sourcing saving. Score two or three suppliers against the same written scope and weight regulatory credibility heaviest. The checklist below is what separates a partner that clears review from one that creates a clinical hold.

• Quality and GxP status: confirm GLP compliance (21 CFR Part 58 or OECD GLP) for every pivotal study, get the named study director in writing, and ask for the recent FDA or competent-authority inspection history before you sign.
• Capacity and lead time: telemetered large-animal cardiovascular slots are the binding constraint far more often than the science. Pin down real availability and a milestone timeline (protocol, in-life, analysis, draft report, final report), and ask what historically causes slippage.
• Modality and indication fit: a lab fluent in small-molecule hERG and telemetry work may be new to a biologic where species selection follows pharmacological relevance, or to a cell or gene therapy with no conventional core battery at all. Match the supplier to your molecule.
• Region and regulatory track record: ask how many comparable programs the team has carried through an actual FDA, EMA, or PMDA review, not just how many studies they have run. A clean submission history is the real credential.
• Data quality and exposure linkage: the QT and core-battery readouts are only as good as the toxicokinetics behind them. Confirm bioanalytical methods are validated to the standard your submission needs, so effects can be expressed in exposure terms a reviewer can map to humans.
• IP and confidentiality: settle ownership of data and any platform-derived assay outputs up front, and have a CDA in place before you share structure or mechanism on a program you may not want disclosed.